Search This Blog

Wednesday, June 6, 2018

Valeant upped to buy by Barclays


Barclays upgraded Valeant Pharmaceuticals (NYSE: VRX) from Equalweight to Overweight with a price target of $29.00 (from $20.00).
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)